Tehran University of Medical Sciences

Science Communicator Platform

Share By
Global Perspectives on Telemedicine-Enabled Medications for Opioid Use Disorder: Practices, Priorities, and Barriers Publisher



Schofield J ; Baldacchino AM ; Ambekar A ; Anaba H ; Butner JL ; Day N ; Ekhtiari H ; Elomari F ; Ferri M ; Kokkolis K ; Kouimtsidis C ; Levola J ; Long J ; Martell D Show All Authors
Authors
  1. Schofield J
  2. Baldacchino AM
  3. Ambekar A
  4. Anaba H
  5. Butner JL
  6. Day N
  7. Ekhtiari H
  8. Elomari F
  9. Ferri M
  10. Kokkolis K
  11. Kouimtsidis C
  12. Levola J
  13. Long J
  14. Martell D
  15. Parker DG
  16. Rahimimovaghar A
  17. Siste K
  18. Steiger S
  19. Zonoozi AK
  20. Tay Wee Teck J

Source: Journal of Telemedicine and Telecare Published:2026


Abstract

Introduction: Telemedicine (TM) has potential to address the global opioid use disorder treatment gap, yet its uptake, priorities, and barriers have not been mapped internationally. Methods: We conducted a cross-sectional, web-based survey (July to November 2024) of clinicians and clinical leaders via the International Society of Addiction Medicine, World Psychiatric Association, and allied contacts. The questionnaire captured telemedicine facilitated medication for opioid use disorder (TMOUD) practices, priorities, and barriers. Responses were summarised overall and stratified by World Bank country-income group and by current TMOUD availability. Results: Sixty-eight experts from 37 countries, 32% from low/middle-income countries (LMICs), participated. General TM use rose from 57% before COVID-19 to 94% in 2024. TMOUD was available in 26 jurisdictions (38%), more often in high-income than LMIC settings (58% vs 11%). Barriers to prescribing were identified, and few settings reimbursed video and telephone consultations equally. Improving treatment retention (69%), reducing missed appointments (62%), and expanding medications to underserved (60%) or remote (57%) populations as top priorities, yet fewer than 40% reported that TMOUD was currently used to meet those goals. Key barriers were inadequate policy support (60%), lack of professional guidance (63%), restrictive regulation (48%), poor digital infrastructure (broadband 29%; e-prescribing 56%), and limited clinician training (54%); almost every barrier was more common in LMICs. Discussion: TMOUD remains uneven and concentrated in high-income countries. Updated clinical guidance, digital connectivity investment and interoperable e-health systems, and targeted workforce development, particularly in LMICs, are needed to realise TM's potential for equitable and effective treatment of opioid use disorder. This global survey fills a critical knowledge gap by documenting expert perspectives across income settings, offering cross-national evidence to inform equitable expansion of TMOUD worldwide. © The Author(s) 2026. This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).